Trace elements and vitamin E status in Nigerian patients with prostate cancer.
BACKGROUND
Prostate cancer is the most common type of cancer among men.


OBJECTIVE
To investigate the trace elements (Se, Zn, Cu and Cd) and vitamin E status of some Nigerian prostate cancer (PCa) patients relative to their prostate-specific antigen (PSA) values.


METHODS
Prostate cancer patients were assigned into groups 1, 2 and 3 with PSA of 5-10 ng/ml, 11-20 ng/ml and > 20 ng/ml, respectively.


RESULTS
The results showed that the levels of whole blood superoxide dismutase (SOD) and serum Se and Zn were significantly lower (p< 0.05) in the PCa patients. Specifically, levels of SOD, Se and Zn decreased by 67%, 30% and 35%; 70%, 52% and 41%; 81%, 58% and 47%, in subjects with PSA of 5-10 ng/ml, 11-20 ng/ml and > 20 ng/ml, respectively. There were no significant differences (p> 0.05) in levels of Cu and Cd. Serum Cu/ Zn ratio were significantly higher in PCa patients. The Cu/ Zn ratios were 1: 1.2: 1.3 for subjects in groups 1, 2 and 3, respectively. Vitamin E levels in PCa patients were significantly lower and followed the order; normal > PSA (5-10) > PSA (11-20) > PSA (> 20).


CONCLUSIONS
Deficiency of vitamin E, Zn and Se may be risk factors for development of PCa.
Adaramoye
O A
OA
Department of Biochemistry, University of Ibadan, Nigeria. aoadaramoye@yahoo.com
Akinloye
O
O
Olatunji
I K
IK
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003300:Copper / Q000032:analysis / Q000097:blood; D006801:Humans; D015227:Lipid Peroxidation; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D009752:Nutritional Status; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood; D014131:Trace Elements / Q000097:blood*; D014810:Vitamin E / Q000097:blood*; D055815:Young Adult; D015032:Zinc / Q000032:analysis / Q000097:blood
D014131:Trace Elements; D014810:Vitamin E; D003300:Copper; D013482:Superoxide Dismutase; D017430:Prostate-Specific Antigen; D015032:Zinc
Methods Enzymol. 1978;52:302-10
672633
Arch Ophthalmol. 2005 Jan;123(1):102-3
15642820
Chem Res Toxicol. 1998 May;11(5):441-8
9585474
Cancer Causes Control. 2005 Nov;16(9):1125-31
16184479
Can J Med Sci. 1952 Aug;30(4):336-9
14954495
Cancer. 2006 Dec 15;107(12):2942-8
17120196
Int Urol Nephrol. 2004;36(1):57-62
15338676
Am J Hum Genet. 2000 Dec;67(6):1367-75
11067781
J Clin Oncol. 2009 Aug 1;27(22):3569-72
19528369
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Mol Cell Biochem. 2005 Dec;280(1-2):1-8
16511951
Nutr Cancer. 1997;28(1):30-5
9200147
J Biol Chem. 1969 Nov 25;244(22):6049-55
5389100
Mol Biol Cell. 2004 Feb;15(2):506-19
14617803
Med Interne. 1987 Oct-Dec;25(4):257-61
3423702
J Natl Cancer Inst. 1998 Mar 18;90(6):440-6
9521168
J Pharm Sci. 1974 Jul;63(7):1084-6
4852370
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):315-20
16492922
J Natl Cancer Inst. 2003 Oct 1;95(19):1477-81
14519754
Mol Cancer Ther. 2005 Jan;4(1):43-50
15657352
Cancer Res. 2004 Jan 1;64(1):19-22
14729601
Neoplasma. 2000;47(1):37-40
10870685
Int J Cancer. 2005 Aug 20;116(2):182-6
15800922
Anticancer Res. 2003 May-Jun;23(3B):2425-33
12894524
Oncogene. 2004 Apr 15;23(17):3080-8
15048090
Science. 2003 May 30;300(5624):1439-43
12775843
Biol Trace Elem Res. 1997 Winter;59(1-3):145-52
9522056
Urol Oncol. 2010 Jul-Aug;28(4):360-7
19171490
J Natl Cancer Inst. 2004 Nov 17;96(22):1669-75
15547179
J Biol Chem. 1999 Jun 18;274(25):17499-504
10364181
Br J Urol. 1983 Oct;55(5):525-8
6194843
Am J Epidemiol. 2007 Aug 1;166(3):280-8
17557900
Proc Nutr Soc. 2005 Nov;64(4):527-42
16313696
Int Urol Nephrol. 1991;23(2):151-4
1713903
Prostate. 1999 Aug 1;40(3):200-7
10398282
J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92
8360931